BioCentury | Oct 31, 2020
Product Development

ICER’s influence on payers could translate to a seat at the table for government drug reviews

...with ICER to provide data on Dupixent dupilumab...
BioCentury | Oct 22, 2020
Product Development

Data Byte: AbbVie’s oral JAK takes the lead in coming competition for Dupixent in atopic dermatitis

...edge in efficacy, compared with three other Phase III programs and the marketed therapy Dupixent dupilumab.The...
...leader Dupixent, an IL-4R and IL-13 inhibitor from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Sanofi (Euronext:SAN; NASDAQ:SNY). Dupixent...
...compound #), baricitinib (Generic), Olumiant (Other) Dupixent (Brand), SAR231893 (Compound #), REGN668 (Compound #), dupilumab (Generic), Dupixent...
BioCentury | Sep 16, 2020
Product Development

Pace of Monjuvi’s growth may dictate how quickly MorphoSys can rebuild its pipeline

...launch of blockbuster atopic dermatitis drug Dupixent dupilumab.Kress’...
BioCentury | Jun 23, 2020
Product Development

June 22 Quick Takes: Invitae acquiring ArcherDX; plus lymphoma approval for Karyopharm, Merck, Nabriva, Myovant, Assembly-AbbVie, Genentech and more

...treat advanced non-small cell lung cancer (NSCLC) and metastatic colorectal cancer. NMPA also approved Dupixent dupilumab...
...RG7440) belantamab mafodotin, J6M0-mcMMAF (2857916, GSK2857916) tislelizumab (BGB-A317) Dupixent (Brand), SAR231893 (Compound #), REGN668 (Compound #), dupilumab (Generic), Dupixent...
BioCentury | Jun 20, 2020
Product Development

Regeneron’s commercial future

...Regeneron also leads U.S. commercialization for PD-1 inhibitor Libtayo cemiplimab-rwlc and co-promotes anti-IL-13 blockbuster Dupixent dupilumab...
...likely require substantial investment or a new partner. Regeneron’s commercial work in the U.S. for Dupixent...
BioCentury | May 28, 2020
Product Development

May 27 Quick Takes: EC approves Zeposia in RRMS; plus Dupixent approved in children, La Jolla, Shionogi, Alnylam and Bold

...label for Dupixent Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Sanofi (Euronext:SAN; NASDAQ:SNY) said FDA approved Dupixent dupilumab...
BioCentury | May 27, 2020
Deals

Sanofi's sale of Regeneron stake for $11B could set stage for both companies' growth through M&A

...market: VEGF fusion protein Zaltrap aflibercept; rheumatoid arthritis treatment Kevzara sarilumab; atopic dermatitis therapy Dupixent dupilumab...
BioCentury | May 21, 2020
Finance

HotSpot heads for clinic with $65M series B round to develop allosteric modulators

...mechanism also has implications in “what an immunologist would describe as Th2-driven diseases, the areas Dupixent...
BioCentury | May 5, 2020
Deals

Alexion sees opportunity in slow-selling Andexxa, buys Portola for $1.4B

...for $1.1 billion on the eve of the JP Morgan Healthcare Conference (see “Lilly Gains Dupixent...
BioCentury | Mar 5, 2020
Politics, Policy & Law

JAMA studies slam drug prices vs R&D costs, Merck’s Frazier pushes back

...Mytesi crofelemer from Jaguar Health Inc. (NASDAQ:JAGX) to $6.4 billion for atopic dermatitis drug Dupixent dupilumab...
Items per page:
1 - 10 of 121